2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 824

Results from a Randomized Controlled Trial of the Safety of the Live Varicella Vaccine in TNF-Treated Patients
Abstract Number: 825

Systemic Sclerosis Deaths at Younger Ages Have Decreased over the past Five Decades
Abstract Number: 826

Immune-Mediated Inflammatory Diseases (IMID) Collectively Rank Among the Leading Causes of Death
Abstract Number: 827

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome
Abstract Number: 828

A Path Model Analysis of the Cognitive Determinants of Physical Activity Among Patients with Fibromyalgia (FM)
Abstract Number: 829

Dietary Intake Does Not Explain Microbiome Alterations or Symptom Severity in Fibromyalgia
Abstract Number: 830

The Efficacy of Non-Pharmacological Interventions for Fibromyalgia: A Systematic Review with Meta-Analysis
Abstract Number: 831

Maintaining Musculoskeletal Health: A Randomized Controlled Prevention Trial Amongst People at High Risk of Developing Chronic Widespread Pain
Abstract Number: 832

Diagnosis of Fibromyalgia: Comparison of AAPT and ACR Criteria
Abstract Number: 833

Effect of a Mobile App to Monitor Patient Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial
Abstract Number: 834

Implementing Patient-Reported Outcome Measures in Clinical Care: Rheumatologist Perspectives on Opportunities and Challenges
Abstract Number: 835

High Baseline Patient’s Compared with Evaluator’s Global Assessment Is Associated with Lower Retention and Remission Rates of First TNF Inhibitor in Psoriatic Arthritis Patients – Data from the EuroSpA Research Collaboration Network
Abstract Number: 836

Patient-Reported Outcomes from a Randomised, Open-Label, Parallel-Group Study Evaluating Ixekizumab versus Adalimumab in Patients with PsA Who Are Biologic DMARD Naïve: 24-Week Results
Abstract Number: 837

Does Discordance Between Baseline Patient’s and Evaluator’s Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network
Abstract Number: 838

Are PROMIS Measures Associated with Minimal Disease Activity in Psoriatic Arthritis?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.